Axial spondyloarthritis affects approximately one in 200 people in the UK
News
Pfizer’s JAK inhibitor Xeljanz shows benefit in COVID-19 pneumonia
Xeljanz reduced the incidence of death or respiratory failure compared to placebo in hospitalised patients
Researchers identify new drug class with potential in BRCA-mutated tumours
POLQ inhibitors could be used to kill PARP inhibitor-resistant cancer cells
Gov’t announces £36m AI research funding boost for NHS
NHSX and Accelerated Access Collaborative (AAC) have backed 38 AI-driven research projects
New NICE guidance supports shared decision making
Guideline offers advice on how to engage people who are accessing care in the shared decision-making process
Ontozry scores MHRA authorisation for focal-onset seizures
Drug approved to treat adult patients with epilepsy which has not been adequately controlled with at least two anti-epileptic therapies
The patient perspective: what’s next for patient advocacy?
by Sarah Woolnough, CEO of Asthma UK and the British Lung Foundation
NICE backs Lilly’s Taltz for axial spondyloarthritis
Drug has been cleared for use in patients whose condition is not controlled well enough with conventional therapy
CureVac’s COVID-19 vaccine misses the mark in late-stage study
Company attributed 47% vaccine efficacy to ‘unprecedented’ amount of circulating variants
Researchers develop COVID-19 antibody test to detect new variants
New antibody tests can detect if an individual has been exposed to COVID-19 variants, including Alpha and Delta variants
Lilly plans head-to-head migraine study comparing Emgality with Nurtec ODT
The primary endpoint of the study is a 50% reduction in monthly migraine headache days
Study demonstrates safety and efficacy of co-administering COVID-19 and flu vaccines
Study co-administered Novavax’s COVID-19 vaccine alongside Seqirus’ flu vaccines
Exscientia expands translational capabilities with Allcyte acquisition
Allcyte specialises in artificial intelligence (AI) based precision medicine
Biogen’s inherited eye disease gene therapy misses the mark in late-stage trial
Gene therapy was being evaluated for the treatment of the rare eye disease choroideremia
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
Imbruvica treatment regimen demonstrated superior progression-free survival compared to Gazyva combo
